JAZZ News and Press, Jazz Pharmaceuticals plc From 11/09/21

Jazz Pharmaceuticals PLC (JAZZ) Q3 2021 Earnings Conference Call November 09, 2021, 16:30 ET Company Participants Andrea Flynn - VP & Head, IR Bruce Cozadd - Co-Founder, Chairman & CEO Daniel Swisher - President Robert Iannone - EVP, Research & Development & Chief Medical Offi...

Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) are up 1.5% in after-hours trading after the company beat Q3 2021 earnings estimates and raised its 2021 guidance. On a non-GAAP basis, Jazz now expects full-year adjusted net income of $925M-$965M, up from $830M-$910M. Revenue was adjust...

Jazz Pharmaceuticals (NASDAQ:JAZZ): Q3 Non-GAAP EPS of $4.20 beats by $0.89; GAAP EPS of -$0.86 beats by $1.39. Revenue of $838.12M (+39.5% Y/Y) beats by $6.07M. Press Release Net leverage ratio reduced by 0.5x to 4.4x1 in the five months following GW transaction close. Raising full year...

Jazz Pharmaceuticals to Participate in Upcoming November Investor Conferences Jefferies London Healthcare Conference 4th Annual Evercore ISI HealthCONx Conference PR Newswire DUBLIN , Nov. 9, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JA...

Jazz Pharmaceuticals Announces Third Quarter 2021 Financial Results And Raises Full Year Earnings Guidance PR Newswire DUBLIN , Nov. 9, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 20...

Jazz Pharmaceuticals to Present Data Showcasing Clinical Advances Across Hematology/Oncology at ASH 2021 Annual Meeting Sixteen new abstracts to be presented, including the first presentation of data from the Rylaze™ (asparaginase erwinia chrysanthemi (recombinant)-rywn) ...

Jazz has announced the launch of its latest drug, Xywav: the first and only treatment option for idiopathic hypersomnia, with the potential for further indications in future. It has recently completed the acquisition of GW Pharmaceuticals and its portfolio of cannabis derived drugs, s...

FT218 PDUFA was delayed by the FDA, reasons unknown, suspected staffing issues at the agency. FT218 has a clear advantage over Xyrem. I am holding tight. For further details see: Avadel Pharmaceuticals: I Am Holding

After a tough September when the S&P 500 fell by 4.8%, the markets have been showing strength again with the index rising more than 5% in October. But many quality stocks haven't been rising of late, and there are a couple of gems out there that investors may want to buy for Novembe...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Identifying stocks to buy on the dip will always be a winning strategy for long-term investors. So you should always keep some companies on the radar to get long when stock prices become more attractive. Therefore, today&#x...